All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visual abstract | Phase III GRAAPH-2014 trial: Nilotinib ± Ara-C in adult patients with Ph+ ALL
The ALL Hub is excited to present a visual abstract summarizing key data from the phase III GRAAPH-2014 trial (NCT02611492) comparing the efficacy and safety of nilotinib with or without high-dose cytarabine in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.1
- Chalandon Y, Rousselot P, Chevret S, et al. Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia. Blood. 2024. Online ahead of print. DOI: 10.1182/blood.2023023502
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox